• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Product ingredient focus of seizure, lawsuit


U.S. marshals seized more than 12,000 eyelash product tubes (Age Intervention Eyelash, Jan Marini Skin Research Inc. [JMSR]) because of the FDA's concerns that it might cause optic nerve damage, macular edema, or uveitis.

San Jose, CA-U.S. marshals seized more than 12,000 applicator tubes of an eyelash product (Age Intervention Eyelash, Jan Marini Skin Research Inc. [JMSR]) valued at a total of $2 million at the request of the FDA because of agency concerns that it might cause optic nerve damage, macular edema, or uveitis.

The FDA described the product as "an unapproved and misbranded drug" because it said the manufacturer claimed that it could increase eyelash growth and as "an adulterated cosmetic" because it contains bimatoprost, which is approved to treat elevated IOP. Use of the eyelash product by patients taking glaucoma medication also containing the prostaglandin analogue could lead to serious side effects, according to the agency.

The eyelash product's manufacturer, however, issued a statement that it has not made the formulation for more than a year and is unaware of any safety issues related to its use. A new version of the product (Age Intervention Eyelash Conditioner) does not contain bimatoprost and has not been embargoed, according to the statement, issued Nov. 16, the same day as the seizure.

The seizure followed the Nov. 7 filing of a lawsuit by Allergan Inc. in U.S. District Court in Santa Ana, CA, against seven companies it said sell products containing prostaglandin analogues such as bimatoprost and promote them to grow eyelashes. Allergan makes a glaucoma medication (Lumigan) that contains bimatoprost and maintains that the other companies are infringing on a patent related to the prostaglandin analogue's ability to help eyelashes grow. Allergan does not make a product specifically for eyelash growth.

The lawsuit names JMSR as well as Athena Cosmetics Inc., Cayman Chemical Co., Civic Center Pharmacy, DermaQuest Inc., Intuit Beauty Inc., and PhotoMedex Inc.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.